Pathological assessment of resection specimens after neoadjuvant therapy for metastatic melanoma

M. T. Tetzlaff, J. L. Messina, J. E. Stein, X. Xu, R. N. Amaria, C. U. Blank, B. A. Van De Wiel, P. M. Ferguson, R. V. Rawson, M. I. Ross, A. J. Spillane, J. E. Gershenwald, R. P.M. Saw, A. C.J. Van Akkooi, W. J. Van Houdt, T. C. Mitchell, A. M. Menzies, G. V. Long, J. A. Wargo, M. A. DaviesV. G. Prieto, Janis M Taube, R. A. Scolyer

Research output: Contribution to journalArticle

Abstract

Background: Clinical trials have recently evaluated safety and efficacy of neoadjuvant therapy among patients with surgically resectable regional melanoma metastases. To capture informative prognostic data connected to pathological response in such trials, it is critical to standardize pathologic assessment and reporting of tumor response after this treatment. Methods: The International Neoadjuvant Melanoma Consortium meetings in 2016 and 2017 assembled pathologists from academic centers to develop consensus guidelines for pathologic examination and reporting of surgical specimens from AJCC (8th edition) stage IIIB/C/D or oligometastatic stage IV melanoma patients treated with neoadjuvant-targeted or immune therapy. Patterns of pathologic response are provided context to inform these guidelines. Results: Based on our collective experience and guided by efforts in well-established neoadjuvant settings like Breast cancer, procedures directing handling of pre- and post-neoadjuvant therapy–treated melanoma specimens are provided to facilitate comparison of findings across different trials and centers. Definitions of pathologic response are provided together with guidelines for reporting and quantifying the extent of pathologic response. Finally, the spectrum of histopathologic responses observed following neoadjuvant-targeted and immune-checkpoint therapy is described and illustrated. Conclusions: Standardizing pathologic evaluation of resected melanoma metastases following neoadjuvant-targeted or immune-checkpoint therapy allows more robust stratification of patient outcomes. This includes recognizing the spectrum of histopathologic response patterns to neoadjuvant therapy and a standard approach to grading pathologic responses. Such an approach will facilitate comparison of results across clinical trials and inform ongoing correlative studies into the mechanisms of response and resistance to agents applied in the neoadjuvant setting.

Original languageEnglish (US)
Pages (from-to)1861-1868
Number of pages8
JournalAnnals of Oncology
Volume29
Issue number8
DOIs
StatePublished - Jan 1 2018

Fingerprint

Neoadjuvant Therapy
Melanoma
Guidelines
Clinical Trials
Neoplasm Metastasis
Therapeutics
Breast Neoplasms
Safety
Neoplasms

Keywords

  • Immune checkpoint blockade
  • Melanoma
  • Neoadjuvant therapy
  • Pathology
  • Targeted therapy

ASJC Scopus subject areas

  • Hematology
  • Oncology

Cite this

Tetzlaff, M. T., Messina, J. L., Stein, J. E., Xu, X., Amaria, R. N., Blank, C. U., ... Scolyer, R. A. (2018). Pathological assessment of resection specimens after neoadjuvant therapy for metastatic melanoma. Annals of Oncology, 29(8), 1861-1868. https://doi.org/10.1093/annonc/mdy226

Pathological assessment of resection specimens after neoadjuvant therapy for metastatic melanoma. / Tetzlaff, M. T.; Messina, J. L.; Stein, J. E.; Xu, X.; Amaria, R. N.; Blank, C. U.; Van De Wiel, B. A.; Ferguson, P. M.; Rawson, R. V.; Ross, M. I.; Spillane, A. J.; Gershenwald, J. E.; Saw, R. P.M.; Van Akkooi, A. C.J.; Van Houdt, W. J.; Mitchell, T. C.; Menzies, A. M.; Long, G. V.; Wargo, J. A.; Davies, M. A.; Prieto, V. G.; Taube, Janis M; Scolyer, R. A.

In: Annals of Oncology, Vol. 29, No. 8, 01.01.2018, p. 1861-1868.

Research output: Contribution to journalArticle

Tetzlaff, MT, Messina, JL, Stein, JE, Xu, X, Amaria, RN, Blank, CU, Van De Wiel, BA, Ferguson, PM, Rawson, RV, Ross, MI, Spillane, AJ, Gershenwald, JE, Saw, RPM, Van Akkooi, ACJ, Van Houdt, WJ, Mitchell, TC, Menzies, AM, Long, GV, Wargo, JA, Davies, MA, Prieto, VG, Taube, JM & Scolyer, RA 2018, 'Pathological assessment of resection specimens after neoadjuvant therapy for metastatic melanoma', Annals of Oncology, vol. 29, no. 8, pp. 1861-1868. https://doi.org/10.1093/annonc/mdy226
Tetzlaff, M. T. ; Messina, J. L. ; Stein, J. E. ; Xu, X. ; Amaria, R. N. ; Blank, C. U. ; Van De Wiel, B. A. ; Ferguson, P. M. ; Rawson, R. V. ; Ross, M. I. ; Spillane, A. J. ; Gershenwald, J. E. ; Saw, R. P.M. ; Van Akkooi, A. C.J. ; Van Houdt, W. J. ; Mitchell, T. C. ; Menzies, A. M. ; Long, G. V. ; Wargo, J. A. ; Davies, M. A. ; Prieto, V. G. ; Taube, Janis M ; Scolyer, R. A. / Pathological assessment of resection specimens after neoadjuvant therapy for metastatic melanoma. In: Annals of Oncology. 2018 ; Vol. 29, No. 8. pp. 1861-1868.
@article{be601608277c409e963205ab7c60a98b,
title = "Pathological assessment of resection specimens after neoadjuvant therapy for metastatic melanoma",
abstract = "Background: Clinical trials have recently evaluated safety and efficacy of neoadjuvant therapy among patients with surgically resectable regional melanoma metastases. To capture informative prognostic data connected to pathological response in such trials, it is critical to standardize pathologic assessment and reporting of tumor response after this treatment. Methods: The International Neoadjuvant Melanoma Consortium meetings in 2016 and 2017 assembled pathologists from academic centers to develop consensus guidelines for pathologic examination and reporting of surgical specimens from AJCC (8th edition) stage IIIB/C/D or oligometastatic stage IV melanoma patients treated with neoadjuvant-targeted or immune therapy. Patterns of pathologic response are provided context to inform these guidelines. Results: Based on our collective experience and guided by efforts in well-established neoadjuvant settings like Breast cancer, procedures directing handling of pre- and post-neoadjuvant therapy–treated melanoma specimens are provided to facilitate comparison of findings across different trials and centers. Definitions of pathologic response are provided together with guidelines for reporting and quantifying the extent of pathologic response. Finally, the spectrum of histopathologic responses observed following neoadjuvant-targeted and immune-checkpoint therapy is described and illustrated. Conclusions: Standardizing pathologic evaluation of resected melanoma metastases following neoadjuvant-targeted or immune-checkpoint therapy allows more robust stratification of patient outcomes. This includes recognizing the spectrum of histopathologic response patterns to neoadjuvant therapy and a standard approach to grading pathologic responses. Such an approach will facilitate comparison of results across clinical trials and inform ongoing correlative studies into the mechanisms of response and resistance to agents applied in the neoadjuvant setting.",
keywords = "Immune checkpoint blockade, Melanoma, Neoadjuvant therapy, Pathology, Targeted therapy",
author = "Tetzlaff, {M. T.} and Messina, {J. L.} and Stein, {J. E.} and X. Xu and Amaria, {R. N.} and Blank, {C. U.} and {Van De Wiel}, {B. A.} and Ferguson, {P. M.} and Rawson, {R. V.} and Ross, {M. I.} and Spillane, {A. J.} and Gershenwald, {J. E.} and Saw, {R. P.M.} and {Van Akkooi}, {A. C.J.} and {Van Houdt}, {W. J.} and Mitchell, {T. C.} and Menzies, {A. M.} and Long, {G. V.} and Wargo, {J. A.} and Davies, {M. A.} and Prieto, {V. G.} and Taube, {Janis M} and Scolyer, {R. A.}",
year = "2018",
month = "1",
day = "1",
doi = "10.1093/annonc/mdy226",
language = "English (US)",
volume = "29",
pages = "1861--1868",
journal = "Annals of Oncology",
issn = "0923-7534",
publisher = "Oxford University Press",
number = "8",

}

TY - JOUR

T1 - Pathological assessment of resection specimens after neoadjuvant therapy for metastatic melanoma

AU - Tetzlaff, M. T.

AU - Messina, J. L.

AU - Stein, J. E.

AU - Xu, X.

AU - Amaria, R. N.

AU - Blank, C. U.

AU - Van De Wiel, B. A.

AU - Ferguson, P. M.

AU - Rawson, R. V.

AU - Ross, M. I.

AU - Spillane, A. J.

AU - Gershenwald, J. E.

AU - Saw, R. P.M.

AU - Van Akkooi, A. C.J.

AU - Van Houdt, W. J.

AU - Mitchell, T. C.

AU - Menzies, A. M.

AU - Long, G. V.

AU - Wargo, J. A.

AU - Davies, M. A.

AU - Prieto, V. G.

AU - Taube, Janis M

AU - Scolyer, R. A.

PY - 2018/1/1

Y1 - 2018/1/1

N2 - Background: Clinical trials have recently evaluated safety and efficacy of neoadjuvant therapy among patients with surgically resectable regional melanoma metastases. To capture informative prognostic data connected to pathological response in such trials, it is critical to standardize pathologic assessment and reporting of tumor response after this treatment. Methods: The International Neoadjuvant Melanoma Consortium meetings in 2016 and 2017 assembled pathologists from academic centers to develop consensus guidelines for pathologic examination and reporting of surgical specimens from AJCC (8th edition) stage IIIB/C/D or oligometastatic stage IV melanoma patients treated with neoadjuvant-targeted or immune therapy. Patterns of pathologic response are provided context to inform these guidelines. Results: Based on our collective experience and guided by efforts in well-established neoadjuvant settings like Breast cancer, procedures directing handling of pre- and post-neoadjuvant therapy–treated melanoma specimens are provided to facilitate comparison of findings across different trials and centers. Definitions of pathologic response are provided together with guidelines for reporting and quantifying the extent of pathologic response. Finally, the spectrum of histopathologic responses observed following neoadjuvant-targeted and immune-checkpoint therapy is described and illustrated. Conclusions: Standardizing pathologic evaluation of resected melanoma metastases following neoadjuvant-targeted or immune-checkpoint therapy allows more robust stratification of patient outcomes. This includes recognizing the spectrum of histopathologic response patterns to neoadjuvant therapy and a standard approach to grading pathologic responses. Such an approach will facilitate comparison of results across clinical trials and inform ongoing correlative studies into the mechanisms of response and resistance to agents applied in the neoadjuvant setting.

AB - Background: Clinical trials have recently evaluated safety and efficacy of neoadjuvant therapy among patients with surgically resectable regional melanoma metastases. To capture informative prognostic data connected to pathological response in such trials, it is critical to standardize pathologic assessment and reporting of tumor response after this treatment. Methods: The International Neoadjuvant Melanoma Consortium meetings in 2016 and 2017 assembled pathologists from academic centers to develop consensus guidelines for pathologic examination and reporting of surgical specimens from AJCC (8th edition) stage IIIB/C/D or oligometastatic stage IV melanoma patients treated with neoadjuvant-targeted or immune therapy. Patterns of pathologic response are provided context to inform these guidelines. Results: Based on our collective experience and guided by efforts in well-established neoadjuvant settings like Breast cancer, procedures directing handling of pre- and post-neoadjuvant therapy–treated melanoma specimens are provided to facilitate comparison of findings across different trials and centers. Definitions of pathologic response are provided together with guidelines for reporting and quantifying the extent of pathologic response. Finally, the spectrum of histopathologic responses observed following neoadjuvant-targeted and immune-checkpoint therapy is described and illustrated. Conclusions: Standardizing pathologic evaluation of resected melanoma metastases following neoadjuvant-targeted or immune-checkpoint therapy allows more robust stratification of patient outcomes. This includes recognizing the spectrum of histopathologic response patterns to neoadjuvant therapy and a standard approach to grading pathologic responses. Such an approach will facilitate comparison of results across clinical trials and inform ongoing correlative studies into the mechanisms of response and resistance to agents applied in the neoadjuvant setting.

KW - Immune checkpoint blockade

KW - Melanoma

KW - Neoadjuvant therapy

KW - Pathology

KW - Targeted therapy

UR - http://www.scopus.com/inward/record.url?scp=85055505227&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85055505227&partnerID=8YFLogxK

U2 - 10.1093/annonc/mdy226

DO - 10.1093/annonc/mdy226

M3 - Article

C2 - 29945191

AN - SCOPUS:85055505227

VL - 29

SP - 1861

EP - 1868

JO - Annals of Oncology

JF - Annals of Oncology

SN - 0923-7534

IS - 8

ER -